Immunovant (IMVT) Free Cash Flow (2019 - 2026)

Immunovant has reported Free Cash Flow for 8 years, with the latest figure at -$95.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 14.23% year-over-year to -$95.1 million; the trailing twelve-month figure through Mar 2026 stood at -$407.3 million (down 8.15% YoY), and the FY2026 full-year result was -$407.3 million, down 8.15% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$95.1 million, down from -$92.3 million in the prior quarter.
• The five-year high for Free Cash Flow was -$20.2 million in Q3 2022, with the low at -$117.4 million in Q2 2025.
• Historically, Free Cash Flow has averaged -$71.8 million across 5 years, with a median of -$65.9 million in 2022.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 210.2% — and 2023, when it climbed 28.01%.
• Immunovant's Free Cash Flow stood at -$46.5 million in 2022, then decreased by 1.58% to -$47.2 million in 2023, then plunged by 112.94% to -$100.6 million in 2024, then rose by 8.2% to -$92.3 million in 2025, then declined by 2.97% to -$95.1 million in 2026.
• The last three Free Cash Flow figures came in at -$95.1 million (Q1 2026), -$92.3 million (Q4 2025), and -$102.5 million (Q3 2025), per Business Quant data.